Skip to content
value.today

Zymogenetics Inc.

Total raised
$16 M
1 round on record
Latest round
$16 M
Nov 2008
First round on record
Nov 2008
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Zymogenetics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2008$16 MNo. 1$10 to $50 million

Zymogenetics Inc.: Raise no. 1, Nov 2008

Investors in this round

2 investors had bought by the notice of Nov 17, 2008: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Wa

People named in the notice

  • Bruce L.A. Carter, Ph.D. · Executive Officer, Director
  • Darren R. Hamby · Executive Officer
  • Douglas E. Williams, Ph.D. · Executive Officer
  • Heather L. Franklin · Executive Officer
  • James A. Johnson · Executive Officer
  • Michael J. Dwyer · Executive Officer
  • Nicole Onetto, M.D. · Executive Officer
  • Suzanne M. Shema, J.D. · Executive Officer
  • Vaughn B. Himes, Ph.D. · Executive Officer
  • David H. MacCallum · Director
  • David I. Hirsch, Ph.D. · Director
  • Edward E. Penhoet, Ph.D. · Director
  • James A. Harper · Director
  • Jonathan S. Leff · Director
  • Judith A. Hemberger, Ph.D. · Director
  • Kurt Anker Nielsen · Director
  • Lars Rebien Sorensen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “*The number of shares to be issued under the warrant and the exercise price is subject to certain adjustments as set forth in the warrant, which is publicly available.”

Signed by James A. Johnson, Executive Vice President, Chief Financial Officer & Treas.. Source: SEC Form D, newest notice filed Nov 17, 2008. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Zymogenetics Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (Nov 2008).

    SEC Form D (revenue range) · Nov 2008

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2008

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Zymogenetics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Zymogenetics Inc.
NameRoleNamed in
Bruce L.A. Carter, Ph.D.Executive officerNov 2008
Darren R. HambyExecutive officerNov 2008
Douglas E. Williams, Ph.D.Executive officerNov 2008
Heather L. FranklinExecutive officerNov 2008
James A. JohnsonExecutive officerNov 2008
Michael J. DwyerExecutive officerNov 2008
Nicole Onetto, M.D.Executive officerNov 2008
Suzanne M. Shema, J.D.Executive officerNov 2008
Vaughn B. Himes, Ph.D.Executive officerNov 2008
Bruce L.A. Carter, Ph.D.DirectorNov 2008
David H. MacCallumDirectorNov 2008
David I. Hirsch, Ph.D.DirectorNov 2008
Edward E. Penhoet, Ph.D.DirectorNov 2008
James A. HarperDirectorNov 2008
Jonathan S. LeffDirectorNov 2008
Judith A. Hemberger, Ph.D.DirectorNov 2008
Kurt Anker NielsenDirectorNov 2008
Lars Rebien SorensenDirectorNov 2008